Review of CLEAR and CheckMate-9ER: Four-Year and 55 Month Follow-Up Data

Opinion
Video

Matthew Campbell, MD, MS, analyzes the crucial efficacy and safety results from the CLEAR trial's 4-year final analysis, incorporating insights on how these findings influence clinical decision-making for treatment-naïve patients with advanced renal cell carcinoma.

  1. Dr Campbell: Please briefly review key efficacy and safety data from the CLEAR trial 4-year final analysis (Motzer et al. J Clin Oncol. 2024),
    • What are the clinical implications of these data for treatment-naïve patients with advanced RCC?
    • In responders, how important is the durability of the response (OS) based on the original response (CR, PR with ≥75% reduction, PR with ≥30% to <75% reduction) for both the intermediate/poor and favorable-risk group?

Recent Videos
Corey Cutler, MD, MPH, and Hannah Choe, MD, experts on GVHD
Aditya Bardia, MD, MPH, FASCO, and Laura Huppert, MD, experts on breast cancer
Martin H. Voss, MD, an expert on kidney cancer
Corey Cutler, MD, MPH, and Hannah Choe, MD, experts on GVHD
Corey Cutler, MD, MPH, and Hannah Choe, MD, experts on GVHD
Aditya Bardia, MD, MPH, FASCO, and Laura Huppert, MD, experts on breast cancer
Aditya Bardia, MD, MPH, FASCO, and Laura Huppert, MD, experts on breast cancer
2 KOLs are featured in this program.
2 KOLs are featured in this program.
Related Content